CMS accelerates Medicare price negotiations for drugs with hyaluronidase, impacting biologic drug pricing and pharmaceutical companies like Halozyme Therapeutics and Johnson & Johnson.
CCS’s AI-driven PropheSee™ platform significantly improves CGM adherence in Medicare diabetes patients, saving $10M+ and advancing preventive chronic care.
CMS issued final rules and updates for Medicare Advantage and Part D programs for 2026, including Inflation Reduction Act implementations and inpatient care protections.
President Trump signs an executive order setting a 30-day deadline for drugmakers to lower prescription drug prices in the U.S. or face new federal limits tied to international prices.
Democrats call on GOP leaders to stop Medicaid cuts and focus on Medicare Advantage upcoding to reduce $50 billion in federal overpayments and protect healthcare coverage.
The Trump administration plans to reintroduce a 'most favored nation' drug pricing model for Medicare, aiming to align U.S. drug prices with lower international rates. This strategy faces industry opposition but could complement existing Medicare drug price negotiations to reduce costs.
Colorado's Journey of Care introduces a dedicated value-based palliative care model targeting Medicare Advantage and special needs plans with interdisciplinary services and telehealth support.
Rep. Spartz introduces the SMART Health Care Act to reduce Medicare and Medicaid waste, address hospital overbilling, enhance rural healthcare access, and reform the 340B drug program.
Health insurance coverage for prescription medications declined with increased restrictions in 2025, impacted by pharmacy benefit manager policies and limited regulations.
CMS's GUIDE Model is reshaping Medicare dementia care with home-based solutions, virtual nursing, and new respite care reimbursements to improve patient outcomes and reduce costs.
